Ilumya Side Effects
Generic name: tildrakizumab
Note: This document contains side effect information about tildrakizumab. Some dosage forms listed on this page may not apply to the brand name Ilumya.
Applies to tildrakizumab: subcutaneous solution.
Serious side effects of Ilumya
Along with its needed effects, tildrakizumab (the active ingredient contained in Ilumya) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking tildrakizumab:
More common
- Body aches or pain
- chills
- cough
- difficulty in breathing
- ear congestion
- fever
- headache
- loss of voice
- nasal congestion
- runny nose
- sneezing
- sore throat
- unusual tiredness or weakness
Incidence not known
- Itching skin
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals
Other side effects of Ilumya
Some side effects of tildrakizumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Less common
- Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
- diarrhea
Rare
- Dizziness
- pain in the arms and legs
For Healthcare Professionals
Applies to tildrakizumab: subcutaneous solution.
Hypersensitivity
Frequency not reported: Hypersensitivity, angioedema, urticaria[Ref]
Immunologic
Very common (10% or more): Infections (e.g., upper respiratory tract infection) (23%)[Ref]
Local
Common (1% to 10%): Injection site reactions (e.g., injection site urticaria, pruritus, pain, reaction, erythema, inflammation, edema, swelling, bruising, hematoma, hemorrhage)[Ref]
Respiratory
Very common (10% or more): Upper respiratory tract infections (e.g., nasopharyngitis, upper respiratory tract infection, viral upper respiratory tract infection, pharyngitis) (14%)[Ref]
Frequently asked questions
- How does Ilumya work to treat psoriasis?
- What are the side effects of Ilumya?
- How is Ilumya administered?
- What are the new drugs for the treatment of plaque psoriasis?
- Skyrizi vs Ilumya. What’s the difference?
- Does Ilumya treat psoriatic arthritis?
- How does Ilumya compare to other treatments?
- How does Ilumya affect my immune system?
- How long does it take Ilumya to work?
More about Ilumya (tildrakizumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (5)
- Drug images
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: interleukin inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
References
1. "Product Information. Ilumya (tildrakizumab)." Merck & Co., Inc (2018):
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.